Related Experiment Video
Updated: Sep 4, 2025

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals
Published on: May 30, 2013
Advancing the prevention and treatment of HIV in children: priorities for research and development
Martina Penazzato1, Claire L Townsend1, Nadia A Sam-Agudu2
1HIV Department, WHO, Geneva, Switzerland.
Insights
Developing safe and effective pediatric HIV treatments is vital. The PADO-HIV group prioritized new drugs and formulations to accelerate access for children globally.
Area of Science:
- Pediatric infectious diseases
- HIV/AIDS research
- Pharmaceutical development
Background:
- Effective pediatric antiretroviral (ARV) drug formulations are essential for HIV treatment and prevention in children.
- The World Health Organization's Paediatric Drug Optimization for HIV (PADO-HIV) group convenes experts to address research gaps.
- Low- and middle-income countries face particular challenges in accessing pediatric HIV medications.
Purpose of the Study:
- To identify priority HIV drugs and formulations for pediatric use.
- To define research gaps in the development of new HIV treatments for children.
- To guide funders, drug developers, and researchers in accelerating access to optimal pediatric HIV therapies.
Main Methods:
- The PADO-HIV 5 meeting (September 27–October 15, 2021) convened global stakeholders and experts.
- Evaluation of existing and novel ARV drug classes, including oral and parenteral long-acting formulations.
- Focused sessions on neonatal HIV treatment and innovative drug delivery technologies were conducted.
Main Results:
- A comprehensive list of medium-term and long-term priorities for pediatric HIV drug development was generated.
- Specific research questions were defined to address identified knowledge and development gaps.
- Key areas for future research and investment were highlighted.
Conclusions:
- The PADO-HIV 5 meeting established critical priorities for advancing pediatric HIV treatment and prevention.
- The defined priorities and research questions aim to accelerate the development and accessibility of optimal HIV drugs for children.
- This strategic guidance is crucial for ensuring children receive the most effective HIV therapies available.
Abstract:
Safe and effective paediatric formulations of the most promising antiretroviral drugs are crucial to advance the treatment and prevention of HIV in neonates, infants, children, and adolescents. The WHO Paediatric Drug Optimization for HIV (PADO-HIV) group brings together stakeholders and experts every 2-3 years to identify priority products and define research gaps in the development of new HIV drugs and formulations for children in low-income and middle-income countries. PADO-HIV 5 met from Sept 27 to Oct 15, 2021. The group evaluated HIV agents from known and novel drug classes, oral and parenteral long-acting formulations, and developments in broadly neutralising antibodies, and included focused sessions on neonates and new delivery technologies. A list of medium-term and long-term priorities was generated, and research questions were defined. This forward-looking analysis is intended to provide guidance to funders, drug developers, and researchers, and to accelerate access for children to the best HIV drugs and formulations.
Related Concept Videos
Sexually Transmitted Infections
Retrovirus Life Cycles
Preventive Healthcare Services
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Levels of Health Promotion and Illness Prevention
In primary prevention, actions taken before disease onset prevent the disease from...

